Operating, investing and financing flows differ from the reported change in cash by 84000000, beyond tolerance 42160000.00.
BAXTER INTERNATIONAL INC (BAX) reported revenue of $11.24B and net income of -$957.00M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BAXTER INTERNATIONAL INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.24B | $10.64B | $10.36B | $10.06B | $12.15B | $11.67B | $11.36B | $11.10B | $10.58B | $10.16B |
| Cost of revenue | $7.86B | $6.65B | $6.21B | $6.51B | $7.43B | $7.09B | $6.60B | $6.34B | $6.11B | $6.05B |
| Gross profit | $3.38B | $3.98B | $4.15B | $3.55B | $4.72B | $4.59B | $4.76B | $4.76B | $4.47B | $4.12B |
| Operating income | -$308.00M | $14.00M | $707.00M | -$2.84B | $1.35B | $1.62B | $1.77B | $1.58B | $1.29B | $745.00M |
| Net income | -$957.00M | -$649.00M | $2.66B | -$2.43B | $1.28B | $1.10B | $1.00B | $1.55B | $602.00M | $4.96B |
| Research & development | $518.00M | $590.00M | $518.00M | $450.00M | $531.00M | $521.00M | $595.00M | $654.00M | $615.00M | $646.00M |
| Weighted-average diluted shares | shares 513.00M | shares 510.00M | shares 508.00M | shares 504.00M | shares 508.00M | shares 517.00M | shares 519.00M | shares 546.00M | shares 555.00M | shares 551.00M |
| Pretax income | -$505.00M | -$289.00M | $242.00M | -$3.25B | $1.12B | $1.29B | $970.00M | $1.62B | $1.10B | $4.95B |
| Income tax expense | $395.00M | $37.00M | $61.00M | -$135.00M | $83.00M | $182.00M | -$41.00M | $65.00M | $491.00M | -$12.00M |
| Diluted EPS | $-1.87 | $-1.27 | $5.23 | $-4.83 | $2.53 | $2.13 | $1.93 | $2.83 | $1.08 | $9.01 |
| Selling, general & administrative | $2.89B | $2.97B | $2.95B | $3.10B | $2.84B | $2.47B | $2.54B | $2.62B | $2.63B | $2.72B |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.97B | $1.76B | $3.08B | $1.62B | $2.95B | $3.73B | $3.34B | $1.84B | $3.39B | $2.80B |
| Total assets | $20.06B | $25.78B | $28.28B | $28.29B | $33.52B | $20.02B | $18.19B | $15.72B | $17.11B | $15.55B |
| Current assets | $6.87B | $8.85B | $9.60B | $8.01B | $8.87B | $8.41B | $7.50B | $5.96B | $7.26B | $6.57B |
| Total liabilities | $13.95B | $18.76B | $19.81B | $22.39B | $24.40B | $11.29B | $10.28B | $7.85B | $8.00B | Unavailable |
| Current liabilities | $2.97B | $6.51B | $6.50B | $4.74B | $4.24B | $3.33B | $3.23B | $2.81B | $2.82B | $2.74B |
| Total equity incl. NCI | $6.10B | $7.02B | $8.47B | $5.90B | $9.12B | $8.73B | $7.91B | $7.87B | $9.11B | $8.22B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $2.23B | $2.05B | $1.92B | $2.68B | $2.45B | $1.92B | $1.65B | $1.67B | $1.48B | $1.43B |
| Accounts receivable | $1.86B | $1.68B | $1.72B | $2.57B | $2.63B | $2.01B | $1.90B | $1.84B | $1.70B | Unavailable |
| Goodwill | $4.93B | $5.28B | $5.79B | $6.45B | $9.84B | $3.22B | $3.03B | $3.00B | $3.10B | $2.60B |
| Long-term debt | $9.47B | $10.37B | $11.09B | $15.23B | $17.15B | $5.79B | $4.81B | $3.48B | $3.51B | $2.78B |
| Accounts payable | $999.00M | $968.00M | $881.00M | $1.11B | $1.25B | $1.04B | Unavailable | Unavailable | Unavailable | Unavailable |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $845.00M | $1.02B | $1.73B | $1.21B | $2.22B | $1.87B | $2.10B | $2.02B | $1.71B | $1.65B |
| Capital expenditures | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Investing cash flow | $2.84B | -$626.00M | $3.21B | -$931.00M | -$11.20B | -$1.18B | -$1.10B | -$916.00M | -$1.29B | -$715.00M |
| Financing cash flow | -$4.22B | -$1.08B | -$3.49B | -$1.44B | $8.24B | -$345.00M | $498.00M | -$2.60B | $93.00M | -$324.00M |
| Net change in cash | -$446.00M | -$784.00M | $1.48B | -$1.23B | -$780.00M | $401.00M | $1.50B | -$1.56B | $617.00M | $588.00M |
| Stock-based compensation | $117.00M | $114.00M | $115.00M | $140.00M | $146.00M | $130.00M | $122.00M | $115.00M | $107.00M | $115.00M |
| Common dividends paid | $348.00M | $590.00M | $586.00M | $573.00M | $530.00M | $473.00M | $423.00M | $376.00M | $315.00M | $268.00M |
| Common share repurchases | Unavailable | $0 | $0 | $32.00M | $600.00M | $500.00M | $1.27B | $2.45B | $564.00M | $292.00M |
| Depreciation & amortization | $981.00M | $997.00M | $984.00M | $1.07B | $867.00M | $823.00M | $789.00M | $771.00M | $750.00M | $800.00M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross margin | 30.1% | 37.5% | 40.1% | 35.3% | 38.9% | 39.3% | 41.9% | 42.9% | 42.3% | 40.5% |
| Operating margin | -2.7% | 0.1% | 6.8% | -28.3% | 11.1% | 13.8% | 15.6% | 14.3% | 12.2% | 7.3% |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | 1.0% | 1.1% | 1.1% | 1.4% | 1.2% | 1.1% | 1.1% | 1.0% | 1.0% | 1.1% |
| Current ratio | 2.31x | 1.36x | 1.48x | 1.69x | 2.09x | 2.52x | 2.32x | 2.12x | 2.57x | 2.40x |
| Revenue YoY growth | 5.7% | 2.7% | 3.0% | -17.2% | 4.1% | 2.7% | 2.4% | 4.9% | 4.1% | Unavailable |
| Net margin | -8.5% | -6.1% | 25.6% | -24.2% | 10.6% | 9.4% | 8.8% | 13.9% | 5.7% | 48.9% |
| R&D / revenue | 4.6% | 5.5% | 5.0% | 4.5% | 4.4% | 4.5% | 5.2% | 5.9% | 5.8% | 6.4% |
| CapEx / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | 25.2% | Unavailable | 7.4% | 14.1% | -4.2% | 4.0% | 44.6% | -0.2% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BAX in the interactive workspace to inspect any figure back to its filing.
Source filings
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
Operating, investing and financing flows differ from the reported change in cash by 96000000, beyond tolerance 10810000.00.